Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 trial of RX-5902 and pembrolizumab in patients with metastatic triple negative breast cancer (mTNBC)

Trial Profile

A Phase 2 trial of RX-5902 and pembrolizumab in patients with metastatic triple negative breast cancer (mTNBC)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; RX 5902 (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2018 According to a Rexahn Pharmaceuticals media release, the date of first patient enrolment in this trial is changed from early 2019 to the second half of 2019.
    • 20 Nov 2018 New trial record
    • 05 Nov 2018 According to a Rexahn Pharmaceuticals media release, the company announced a clinical trial collaboration agreement with Merck for this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top